key: cord-0724644-5hb1ebyx authors: Shi, Hui; Zuo, Yu; Navaz, Sherwin; Harbaugh, Alyssa; Hoy, Claire K.; Gandhi, Alex A.; Sule, Gautam; Yalavarthi, Srilakshmi; Gockman, Kelsey; Madison, Jacqueline A.; Wang, Jintao; Zuo, Melanie; Shi, Yue; Maile, Michael D.; Knight, Jason S.; Kanthi, Yogendra title: Endothelial cell‐activating antibodies in COVID‐19 date: 2022-02-17 journal: Arthritis Rheumatol DOI: 10.1002/art.42094 sha: 112320a78824b16b630c076bda8fcc283099c9c8 doc_id: 724644 cord_uid: 5hb1ebyx OBJECTIVE: While endothelial dysfunction has been implicated in the widespread thrombo‐inflammatory complications of coronavirus disease‐19 (COVID‐19), the upstream mediators of endotheliopathy remain for the most part cryptic. Our aim was to identify circulating factors contributing to endothelial cell activation and dysfunction in COVID‐19. METHODS: Human endothelial cells were cultured in the presence of serum or plasma from 244 patients hospitalized with COVID‐19 and plasma from 100 patients with non‐COVID sepsis. Cell adhesion molecules (E‐selectin, VCAM‐1, and ICAM‐1) were quantified by in‐cell ELISA. RESULTS: Serum and plasma from patients with COVID‐19 increased surface expression of cell adhesion molecules. Furthermore, levels of soluble ICAM‐1 and E‐selectin were elevated in patient serum and tracked with disease severity. The presence of circulating antiphospholipid antibodies was a strong marker of the ability of COVID‐19 serum to activate endothelium. Depletion of total IgG from antiphospholipid antibody‐positive serum markedly restrained upregulation of cell adhesion molecules. Conversely, supplementation of control serum with patient IgG was sufficient to trigger endothelial activation. CONCLUSION: These data are the first to suggest that some patients with COVID‐19 have potentially diverse antibodies that drive endotheliopathy, adding important context regarding thrombo‐inflammatory effects of autoantibodies in severe COVID‐19. There are several likely synergistic mechanisms by which SARS-CoV-2 infection may result in COVID-19-associated coagulopathy including cytokine release that activates leukocytes, endothelium, and platelets; direct activation of various cells by viral infection; and high levels of intravascular neutrophil extracellular traps (NETs) (1) . The latter are inflammatory cell remnants that amplify thrombosis (2) . COVID-19-associated coagulopathy may manifest with thrombosis in venous, arterial, and microvascular circuits. The incidence of venous thromboembolism is particularly notable in severe COVID-19 (10% to 35%) with autopsy series suggesting that as many as 60% of those who succumb to COVID-19 are impacted (3) . Recently, there have been a number of descriptions of what appears to be de novo autoantibody formation in individuals with severe COVID-19. One example replicated by multiple groups is the detection of antibodies reminiscent of the antiphospholipid antibodies (aPL) that mediate antiphospholipid syndrome (APS) in the general population. In APS, patients form durable autoantibodies to phospholipids and phospholipid-binding proteins such as prothrombin and beta-2-glycoprotein I (β2GPI). These autoantibodies then engage cell surfaces, where they activate endothelial cells, platelets, and neutrophils and thereby tip the blood:vessel wall interface toward thrombosis. While viral infections have long been known to trigger transient aPL (4) , mechanisms by which these potentially short-lived antibodies may be pathogenic have not been deeply characterized. To this end, our group recently found that IgG fractions from patients with COVID-19 were enriched for aPL and potentiated thrombosis when injected into mice (5) . Intriguingly, the circulating B cell compartment in COVID-19 appears similar to the autoimmune disease lupus, whereby naïve B cells rapidly take an extrafollicular route to becoming antibody-producing cells (6) , and in doing so bypass the normal tolerance checkpoints against autoimmunity provided by the germinal center. Here, we were initially interested in the extent to which circulating NET remnants might be an important activator of endothelial cells. We then also necessarily turned our attention to aPL as potential markers of COVID-19 serum and polyclonal IgG fractions with strong endothelial cell activating-potential. Purification of human IgG. IgG was purified as we have described previously (5) . In-cell ELISA and neutrophil adhesion. In-cell ELISA and neutrophil adhesion were by protocols that we have described previously (7) . Quantification of antibodies and biomarkers. aPL were quantified using Quanta Lite® kits (Inova Diagnostics Inc.). Soluble E-selectin and ICAM-1 were quantified by ELISA (DY724 and DY720, R&D Systems). Myeloperoxidase-DNA complexes were quantified as has been previously described (8) . Cell-free DNA was quantified using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, P11496). Citrullinated histone H3 was quantified by ELISA (Cayman, 501620). Calprotectin was quantified by ELISA (DY8226, R&D Systems). Serum samples were collected from 118 patients hospitalized with COVID-19 at an academic hospital. The average age of this cohort was 62, while 47% were female and 42% were Black/African American (Supplemental Table 1 ); 35% were receiving mechanical ventilation. Serum from COVID-19 patients were added to earlypassage HUVEC, and the expression of cell adhesion molecules was determined after 6 hours via a custom in-cell ELISA compatible with the Biosafety Level-3 facility per institutional guidelines ( Figure 1A) . As compared with serum samples from 38 healthy controls, the COVID- We were able to obtain sufficient serum from an additional 126 hospitalized COVID-19 patients to expand the ICAM-1 testing. These patients had a similar profile to the original 118 patients as shown in Supplemental Table 1 , and also in terms of upregulating surface ICAM-1 (Supplemental Figure 3) . Considering all 244 patients together, serum from patients requiring mechanical ventilation upregulated ICAM-1 more strongly that did serum from patients who were hospitalized but not requiring mechanical ventilation (p<0.01, Figure 1E ). We also measured levels of soluble ICAM-1 and E-selectin in patient serum. We found significantly higher levels of both soluble ICAM-1 and E-selectin in COVID-19 serum as compared with healthy controls ( To determine the extent to which this phenomenon might extend to critically ill patients without COVID-19, we matched 100 patients with sepsis and admitted to the intensive care (plasma obtained in the pre-COVID era) to our COVID-19 cohort (n=72 plasma samples available) by age and comorbidities (Supplemental Table 2 ). More patients in the sepsis cohort required mechanical ventilation (65% versus 46%). We then stimulated HUVEC with plasma and determined the surface expression of ICAM-1. While a subset of the sepsis plasma elicited high expression of surface ICAM-1, the group as a whole was not significantly different from the controls ( Figure 1H) . Meanwhile, COVID-19 plasma demonstrated more activation than either control or sepsis plasma ( Figure 1H ). Taken together, these data indicate that COVID-19 serum and plasma contain factors capable of activating endothelial cells. Table 1) . Taken together, these data demonstrate modest correlations between NETs/thrombo-inflammation and the ability of COVID-19 serum to activate endothelial cells. Association of aPL with the endothelial cell-activating potential of COVID-19 serum. We next reasoned that COVID-19-associated autoreactive antibodies might activate endothelial cells. In pursuit of such antibody fractions, we focused on the IgG and IgM isotypes of three types of aPL: anticardiolipin, anti-β 2GPI, and anti-phosphatidylserine/prothrombin (anti-PS/PT). As is detailed in Supplemental Table 3 , 45% of subjects were positive for at least one antibody based on the manufacturer's cutoff and 25% were positive with a more stringent cutoff of ≥40 units. The vast majority of positive results were either anticardiolipin (IgG=3% and IgM=25% of the cohort, respectively) or anti-PS/PT (IgG=24% and IgM=15% of the cohort, respectively). It should also be noted that there were strong correlations amongst many of the antibodies, for example anticardiolipin IgG and anti-PS/PT IgG (r=0.51, p<0.0001) and anticardiolipin IgM and anti-PS/PT IgM (r=0.53, p<0.0001); all correlations are detailed in Supplemental Table 4 . Furthermore, aPL levels tracked to some extent with clinical biomarkers, especially levels of circulating NETs (Supplemental Table 5 ). None of the aPL were detected at appreciable levels in the healthy control serum (2 positive tests) and plasma (1 positive test) used in this study (Supplemental Tables 6 and 7) . Interestingly, we detected strong correlations between anticardiolipin and anti-PS/PT antibodies and the three markers of endothelial cell activation (E-selectin, VCAM-1, and ICAM-1) ( Table 1 ). The only correlation that was not statistically significant was between anti-PS/PT IgM and VCAM-1 ( Table 1) . We additionally performed logistic regression analysis after setting a positive/negative threshold for cell adhesion molecule upreguation that was 2 standard deviations above the control mean (Supplemental Table 8 ); anticardiolipin IgG levels were significantly higher in E-selectin-and VCAM-1-positive patients (p=0.001 and p=0.003, respectively), while anti-PS/PT IgG levels were significantly higher in ICAM-1-positive patients (p=0.018). We also measured the same aPL in the aforementioned sepsis cohort (Supplemental Table 9 ). Of the 100 patients, 29 were positive for any aPL with 23 positive at the more stringent cutoff of ≥40 units. In contrast to the COVID-19 cohort, the vast majority of positive tests were for anti-PS/PT IgM, the levels of which demonstrated a correlation with the ability of plasma to upregulate ICAM-1 (r=0.29, p<0.01, Supplemental Table 10 ). In summary, we detected correlations between various aPL and endothelial cell activation in COVID-19, and to some extent in sepsis. To determine whether upregulation of E-selectin, VCAM-1, and ICAM-1 is associated with increased adhesive functions of HUVEC, we performed a neutrophil adhesion assay. We pooled serum from three COVID-19 patients with positive anticardiolipin IgG (mean=29 GPL) and separately five COVID-19 patients with positive anti-PS/PT IgG (mean=54 units) activity. We then stimulated HUVEC with the pooled serum. Compared with control serum, both COVID samples significantly increased adhesion of neutrophils to endothelial cells (Figure 2A) . We next sought to determine the extent to which total IgG fractions from COVID-19 patients could directly activate HUVEC. To this end, we subjected the aforementioned pooled serum (anticardiolipin IgG-positive and anti-PS/PT IgG-positive) to either mock or IgG depletion. IgG depletion did not result in significant removal of other serum proteins of note such as calprotectin (Supplemental Figure 6 ). As compared with mock depletion, total IgG depletion completely abrogated the ability of both pooled samples to upregulate endothelial cell E-selectin (Figure 2B) , VCAM-1 ( Figure 2C ) and ICAM-1 ( Figure 2D ). We next purified a small quantity of total IgG from each pool and added it to control serum that had been depleted of its own IgG. The COVID-19 IgG-supplemented control serum now demonstrated an ability to increase expression of surface ICAM-1 (Figure 2E) . In contrast, IgG purified from COVID-19 serum that tested negative for both anticardiolipin and anti-PS/PT IgG did not increase expression of ICAM-1 (Supplemental Figure 7) . Taken together, these data indicate that the presence of aPL correlates with COVID-19 IgG samples that can activate endothelial cells. Here, we report that serum from COVID-19 patients activate cultured endothelial cells to express surface adhesion molecules integral to inflammation and thrombosis, namely ICAM-1, E-selectin, and VCAM-1. Furthermore, we found that for at least a subset of serum samples from patients with COVID-19, this activation could be mitigated by depleting total IgG. The role of aPL in activating endothelial cells has been demonstrated both in vitro and in vivo (9) . For example, IgG fractions from APS patients have long been known to activate HUVEC, as reflected by increased monocyte adherence and expression of adhesion molecules. It is intriguing that while most characterization of endothelium in the APS field has focused on activation of the endothelium by anti-β 2GPI antibodies (10), these were only rarely detected in our cohort. Interesting recent work demonstrates the ability of phospholipid-binding, "cofactorindependent" antibodies to also activate endothelium in APS (11) . Of course, it should be noted that all experiments performed here were with total IgG fractions and not affinity-purified aPL. Therefore, aPL may mark antibody profiles in severe illness, quite possibly polyclonal, that activate the endothelium and steer the normally quiescent blood:vessel interface toward inflammation and coagulation. In addition to our findings (5) , several other groups (12) have also provided evidence for the de novo formation of pathogenic autoantibodies in COVID-19. For example, an interesting study used a high-throughput autoantibody discovery technique to screen a cohort of COVID-19 patients for autoantibodies against 2,770 extracellular and secreted proteins (13) . The authors found a tendency for autoantibodies to be directed against immunomodulatory proteins including cytokines, chemokines, complement components, and cell surface proteins. This is further bolstered by our data suggesting correlations amongst aPL species in serum from patients with COVID-19. Beyond COVID-19, we were intrigued to find that approximately one-quarter of sepsis patients had at least one positive aPL test, mostly anti-PS/PT IgM. Given that anti-PS/PT IgM levels tracked with the ability of plasma to activate endothelial cells, we posit that a similar autoreactive antibody-mediated, endothelial cell-activating mechanism may occur in some patients with sepsis, a state in which infection and the host immune response conspire to perturb the vasculature (14) . Of particular note, infections causing critical illness have long been known to be potential triggers of autoantibodies, and in particular aPL (4, 15) . Although infection-associated aPL have typically been described as transient (16) , a recent systematic review found that one-third of individuals found to have positive aPL in the setting of a virusassociated thrombotic event continue to have durably-positive aPL for at least several months (15) . Based on our data, studies with long-term clinical and serological follow-up of patients may be necessary to better define the natural history of COVID-19 and non-COVID sepsis. There are several potential clinical implications of our findings. A consideration that warrants further investigation is whether patients with severe COVID-19 should be screened for aPL to evaluate their risk of thrombosis and progression to respiratory failure, and whether patients with high aPL titers might benefit from treatments used in traditional cases of severe APS such as therapeutic anticoagulation, complement inhibition, and plasmapheresis. At the same time, determining the extent to which aPL are direct mediators of the endothelial cell phenotypes observed here, or perhaps highlight polyclonal antibody fractions likely to activate endothelial cells, is an important question deserving of future research. This study has additional limitations including a lack of a direct readout of macrovascular thrombosis available in other wellconducted studies (17) given aggressive anticoagulation used at our center early in the pandemic, and an as yet incomplete understanding of mechanisms by which aPL-associated IgG fractions activate endothelial cells. However, given the urgency of COVID-19 research, we believe these issues are counterbalanced by the relatively large sample size and the heretofore unknown discovery of endothelial cell-activating antibody profiles in some COVID-19 serum. Indeed, these data also put the diffuse organ involvement of COVID-19 into context, where a non-specific humoral response to the illness may disrupt the normally quiescent endothelium and potentiate vascular inflammation. As we await definitive solutions to the pandemic, these findings add important context to the complex interplay between SARS-CoV-2 infection, the human immune system, and vascular immunobiology. repeated on 3 different days, and bars represent mean and standard deviation. Groups were compared by 2-sided paired t-test; *p<0.05 and **p<0.01. E, IgG (100 μg/ml) was purified from the pooled samples referenced in A-C, and then spiked into control serum that had been depleted of IgG. Activation of HUVEC was determined after culture for 6 hours as defined by surface expression of ICAM-1. Groups were compared by one-way ANOVA with correction for multiple comparisons by Tukey's test; **p<0.01. Neutrophil extracellular traps in COVID-19 Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Annals of internal medicine Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 Endotheliumprotective, histone-neutralizing properties of the polyanionic agent defibrotide Netting neutrophils in autoimmune small-vessel vasculitis Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies Lipid presentation by the protein C receptor links coagulation with autoimmunity New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19. medRxiv : the preprint server for health sciences Diverse functional autoantibodies in patients with COVID-19 Inflammation, Infection and Venous Thromboembolism Systematic review of case reports of antiphospholipid syndrome following infection Antiphospholipid syndrome infectious origin Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome The authors are indebted to all the individuals with COVID-19 and sepsis who participated in this study, and to the frontline workers during the pandemic.